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With the growing understanding of complex diseases, the focus of drug discovery has shifted from the
well-accepted ‘‘one target, one drug’’ model, to a new ‘‘multi-target, multi-drug’’ model, aimed at system-
ically modulating multiple targets. In this context, polypharmacology has emerged as a new paradigm to
overcome the recent decline in productivity of pharmaceutical research. However, ﬁnding methods to
evaluate multicomponent therapeutics and ranking synergistic agent combinations is still a demanding
task.
At the same time, the data gathered on complex diseases has been progressively collected in public
data and knowledge repositories, such as protein–protein interaction (PPI) databases. The PPI networks
are increasingly used as universal platforms for data integration and analysis. A novel computational net-
work-based approach for feasible and efﬁcient identiﬁcation of multicomponent synergistic agents is
proposed in this paper. Given a complex disease, the method exploits the topological features of the
related PPI network to identify possible combinations of hit targets. The best ranked combinations are
subsequently computed on the basis of a synergistic score. We illustrate the potential of the method
through a study on Type 2 Diabetes Mellitus. The results highlight its ability to retrieve novel target can-
didates, which role is also conﬁrmed by the analysis of the related literature.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Over the past decade, there has been a signiﬁcant decrease in
the rate of translation of new drug candidates into effective clinical
therapeutic agents. Many reasons have been argued for such de-
cline of productivity in pharmaceutical research. The assumption
of the current approach is that safer, more effective drugs will re-
sult from designing very selective ligands for a good target. Ideally,
a good target would regulate the pathway of interest: thus, block-
ing the target would result in effective medical treatment. The
rationale for this strategy is that the speciﬁcity to the selected tar-
get leads to reduced side effects that may be caused by undesir-
able, non-therapeutic off-target binding. Recently it has been
appreciated that many effective drugs (in therapeutic areas as di-
verse as oncology, psychiatry and antiinfectives) act on multiple
rather than single targets, a phenomenon known as polypharma-
cology [1].
Searching for multi-target drugs is a novel and emerging drug
discovery paradigm based on the idea that improved therapeutic
efﬁcacy and safety can be achieved by designing new individualchemical entities that can simultaneously target different molecu-
lar aspect of a given disease [2]. A multi-target approach to dis-
cover innovative medicines is necessary given the multifaceted
nature of several complex diseases. In fact, the multidimensional
view of diseases is replacing the linear causality model based on
the ‘‘one disease, one gene, one target’’ and the ‘‘one single-target
drug’’ paradigms. A ﬁrst step toward this change is the multi-target
strategy, where different targets at different key points within the
same or concurrent pathogenic pathways are carefully chosen for
their potential additive or synergistic effects.
However, the rational design of multi-target drugs faces consid-
erable challenges. These mainly arise from the need for new meth-
ods to validate target combinations and to identify preliminary hit
compounds.
One of the fundamental advantages of multicomponent thera-
peutics is the production of ‘‘synergy’’, that is, the combinational
effect must be greater than the sum of the individual effects.
Although some experimental methods have been proposed to
screen favourable drug combinations by disease-relevant pheno-
typic assays, the high-throughput identiﬁcation of synergistic
agent combinations arising from numerous agents remains an
unresolved issue. In this context, computational approaches that
take advantage of the rapid accumulation of massive data may pro-
vide a more promising and desirable strategy for multicomponent
drug studies.
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the equilibrium of a system, we need multi-targeted drugs capable
of modulating the balance of the system in an attempt to minimise
this change.
In order to develop drugs that meet those standards it is essen-
tial to design the system (i.e. network) best describing the complex
‘‘omics’’ interactions (i.e. nodes) of the underlying disease. In par-
ticular, a network-based representation and analysis seems the
elective strategy to deal with multicomponent therapeutics in
complex diseases, as it ‘‘naturally’’ offers new therapeutic views
and recommendations for drug repositioning [3,4]. This approach
is very powerful when networks are coupled with data collected
with -omics technologies (proteomics and genomics) for uncover-
ing dynamic correlations within targets and drug actions. More-
over, it can provide efﬁcient tools to better deﬁne the global
picture of disease status and dynamic interactions of pathological
targets at the molecular network level; likewise, all of these infor-
mations can be used for drug design based on network targeting
[4].
A number of recent studies have been performed to analyse
multi-target drug discovery with a network-based approach [4,5].
In particular, many works revealed that protein and ligand promis-
cuity is a phenomenon much more common then previously
hypothesised. Yildirim et al. applied network analysis to drugs
and their targets by integrating publicly available drug data [6].
The resulting network of polypharmacological interactions was
dense in nature and revealed not only that a single target can often
bind multiple drugs, but also that it is far more common than ex-
pected that single drugs modulate several different molecular tar-
gets, which may be involved in multiple diseases.
Li et al. have proposed an integrated network model, which is
aimed to transfer correlations between drugs to the interactions
among their molecular target [7]. The authors computed a score
based on two elements, a Topology Score (TS) and an Agent Score
(AS), which were used for assessing agents interactions with the
biological targets. The TS is derived from the topological features
of the background network related to certain disease condition,
while the AS is used to quantify the effect of two agents on disease
phenotype, as derived by applying text mining on the OMIM dis-
ease descriptions. The score was calculated multiplying TS and
AS. The higher the score, the greater the probability of synergy of
the drug combination.
Li et al. used a biological network-based multi-target computa-
tional estimation scheme to screen anticoagulant activity of a ser-
ies of argatroban intermediates and eight natural products based
on afﬁnity predictions from their multi-target docking scores and
on a network efﬁciency analysis [8]. This scheme has been derived
from the traditional single agent virtual screening method, which
relies on evaluating binding afﬁnity targets. Li et al. built a network
by using the Reactome repository and designed a method for
selecting targets that can be applied only to the proteins whose vir-
tual screening is known.
We hereby propose a novel computational approach for a efﬁ-
cient identiﬁcation of multicomponent synergies that relies on a
network-based representation of the complex disease.
Our work differs from the papers described above. In particular,
instead of performing a drug–drug and a drug–target network as
described in [6], our approach focuses on disease-speciﬁc protein
networks to ﬁnd new target candidates.
The network is created by integrating different data sources to
represent the disease efﬁciently. In this way, the prediction of
the targets also includes the proteins for which a virtual screening
is unknown or infeasible, differently from [8]. Although a number
of computational approaches have been developed to integrate
data from multiple sources to propose new drug candidates, rela-
tively few of them focus on identifying and ranking potential tar-gets, as our investigation suggests. Our work was inspired by the
paper of Zhang et al. [9], which ranked potential targets for a spe-
ciﬁc drug, thus limiting the target discovery to a drug, instead of
focusing on a speciﬁc disease. The authors also built a network
whose nodes were genes. In our case, we build a protein–protein
interaction network in order to increase the number of possible
associations retrieved, i.e. the physical interaction between pro-
teins and their binding type.
A detailed description of the proposed approach and the results
obtained for the selected disease is reported in the following of the
paper. Given the social impact, the scientiﬁc interest and the high
number of available data sets, we chose to test our methods on
type 2 Diabetes Mellitus (T2DM), a noteworthy example of mul-
ti-factorial and complex disease [10].2. Material and methods
As mentioned in the previous section, we developed a network-
based method that aims at extracting the core disease causative
pathways and then at proposing possible combinations of targets
suitable for a multicomponent therapy.
The main steps of the methods are described in the following
sections.
2.1. Network design
The ﬁrst step involved the creation of a protein–protein interac-
tion (PPI) network for the disease under study, by integrating dif-
ferent databases and high-throughput datasets. In the resulting
biological network, the nodes are proteins and the edges represent
various biological associations among them.
The PPI network was built by ﬁrst retrieving the proteins in-
volved in the Reactome disease pathways [11] and then, on the ba-
sis of the proteins retrieved so far, by retrieving the human PPI data
in the STRING repository [12]. We selected only the relationships
derived from experimental data and with a conﬁdence score > 0.7,
corresponding to high conﬁdence for the association predicted by
STRING [13]; this allowed us building a network with weights on
the edges: the weights are equal to the conﬁdence of the
association.
2.1.1. Disease network
Starting from the PPI network, the next step was to ﬁnd out
which proteins are differentially expressed in the disease state.
Considering that such proteins correspond to the nodes of the net-
work, we called them disease proteins (DP). To identify the DP, we
used human microarray data downloaded from Stanford Micro-
array Database (SMD) [14] and Gene Expression Omnibus (GEO)
[15]. This selection was computed on the basis of the fold change
(FC) obtained from case-versus-control comparisons with a cutoff
of 2. Then, we matched these genes with the genes that encode
the network’s proteins in order to identify the over- or under-ex-
pressed nodes. This step clearly has limits, as it does not take into
account post-translational proteins modiﬁcation and regulation.
2.1.2. Target features
Once DPs had been identiﬁed, the next step consisted in net-
work targeting. Instead of selecting all the network nodes as possi-
ble targets, we decided to introduce some constraints that allowed
restricting the nodes space. We called these proteins SourceT ST, be-
cause they are the sources of a potential synergistic pharmacolog-
ical effect.
First, we decided to discard hub nodes, i.e. highly connected
nodes. Besides the special topological and functional signiﬁcance
in a network, hubs have also special biological properties: they
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found to play a central role in modular organisation of the protein
interaction network and they are used in traditional pharmacology
as standard targets [16]. Given their high number of neighbours,
acting on hubs might provoke a large number of side effects. To
identify the hubs we used a method proposed by Vallabhajosyula
et al. [16]. The method grounds on the different topological prop-
erties of hub and non-hub nodes: hubs form subgraphs which
are loosely connected to each other, while non-hub nodes may play
the role of connecting hubs subgraphs [16]. Vallabhajosyula et al.
identify hubs by ﬁrst constructing a node list ranked by their
decreasing degree. Then, following an iterative process, the ﬁrst
nodes in the ranked list are extracted and the relative connectivity
of their subgraphs1 is calculated. It is expected that the relative con-
nectivity will initially decrease by adding nodes from the ordered
list, since the hub nodes, which are highly ranked, are not connected
to each other. The process is repeated until the relative connectivity
increases; this, in fact, is assumed to mark the transition between
hub and non-hub nodes [16].
The second constraint involves bridging centrality, a centrality
measure proposed by Hwang et al. [17]. Unlike common centrality
measures, bridging centrality can discriminate bridging nodes, i.e.
the nodes that are crucial to dispatch information to the network
topological structures: such nodes are typically located between
highly connected regions. The bridging centrality BR(i) of a node
is the product of the betweenness centrality (B) and the bridging
coefﬁcient (BC), which measures the global and local features of
a node, respectively [17]. The bridging centrality of a node i is de-
ﬁned by the equation:
BRðiÞ ¼ BðiÞBCðiÞ ð1Þ
B is a measure of the centrality of a node in a network, and is
usually calculated as the fraction of shortest paths between node
pairs that pass through the node of interest.2 By counting only
the shortest paths, however, the conventional deﬁnition implicitly
assumes that information spreads only along the shortest paths. Dif-
ferently from [17], we resorted to Random Walk Betweenness Cen-
trality (RWBC), as proposed by [18]. The main idea is that, instead
of taking into account shortest paths only, it considers all possible
paths between two nodes. In particular, given R the matrix which
(s, t) th element Rst contains the probability of a random walk from
s to t, passing through the node i. Then, the Newman’s betweenness
centrality RWBC(i) of node i is deﬁned to be RWBCðiÞ ¼Ps–i–tRst [18].
The other term of the Eq. (1) is the bridging coefﬁcient BC, a
measure that assesses the local bridging characteristics in the
neighbourhood and penalises nodes that have a high degree of con-
nectivity. The bridging coefﬁcient evaluates if a node is located be-
tween high degree nodes, and it is deﬁned as:
BCðiÞ ¼ dðiÞ
1
P
v2NðiÞ
1
dðvÞ
ð3Þ
where d(i) is the node v degree, and N(i) is the set of neighbours of
node i.1 Computed as the ratio between the size of the maximum connected component
and the number of nodes of the subgraphs.
2 Suppose that shsti is the number of shortest paths from vertex s to vertex t that
pass through i, and suppose that nst is the total number of shortest paths from s to t.
Then the betweenness of vertex i is:
BðiÞ ¼
P
s<tsh
st
i =nst
1
2nðn 1Þ
ð2Þ
where n is the total number of vertices in the network. B is thus a measure of the inﬂu-
ence a node has over the spread of information through the network [18].We selected as bridging nodes those in the highest quartile of
bridging centrality values. This threshold has been suggested by
Hwang et al. and it has been also conﬁrmed by empirical studies
on several real world network systems [17].
The last constraint on the ST nodes is related to their druggabil-
ity, a term used in drug discovery to describe a biological target
such as a protein that is known or is predicted to bind to a drug
with high afﬁnity. To classify a protein as druggable, we introduced
two parameters.
First, the proteins had to be included in STITCH [19], a data
repository that allows to explore known and predicted interactions
of chemicals and proteins. Since we were interested only in the
associations with drugs and not with all the chemical compounds,
the target proteins selected were only the ones with a known inter-
action with a compound already classiﬁed in Anatomical Thera-
peutic Chemical (ATC) Classiﬁcation System. In analogy with
what we did for the interactions retrieved from STRING, we se-
lected only the associations with high conﬁdence (here conﬁdence
score > 0.9).
Second, the localisation of the proteins was restricted to be in
the extracellular space or in the cell membrane. In these areas,
an efﬁcient interaction or binding with a drug candidate is more
probable.
Therefore, the proteins with a drug association stored in STRING
and corresponding to the localisation constraints mentioned above
were selected as druggable nodes.
The nodes in the network with the previously described fea-
tures (i.e. non-hub, with high bridging centrality and druggable)
were identiﬁed as possible targets (ST). It should be noted that a
ST could be a generic protein in the network as well as a disease
protein (DP).2.2. Scoring system
The following step concerned the selection of the ST combina-
tions that are more interesting for a polypharmacological ap-
proach. To this aim, we introduced a score called Topological
Score of Drug Synergy (TSDS), a function that assigns a score to each
combination of ST on the basis of the target topological features.
The TSDS was calculated in 3 steps.
1. Node reachability. A function TtoDP assigns a score to every ST
target on the basis of the topological reachability of a known
DP. The TtoDP was calculated as follows:TtoDPðt;dÞ ¼
PNsh
sh¼1
Q
i;jwi;j
Nsh
8ði; jÞ 2 sh ð4Þwhere Nsh is the total number of shortest paths between the target t
and the Disease Node d, (i, j) is a pair of nodes that belongs to the
shortest path sh and wi,j is the weight on the edge between the
two nodes. The function multiplies the weights on the edges in a
shortest path ðQi;jwi;jÞ. A ST node t with high weights on the edges
of its shortest paths will obtain a higher score. In this way, the best
nodes are the ones with the highest conﬁdences in their predicted
relationships.
2. Global effect. The Eq. (5) quantiﬁes a score for the interaction of
each target with a drug on all the DP in the network.TtoallDPðtÞ ¼
XNd
d¼1
TtoDPðt; dÞ
Nd
ð5Þwhere Nd is the total number of DP and TtoDP(t,d) is calculated as in
Eq. (4). This function allows to construct a ranked list of the targets
taking into account their global effect on all the DP proteins.
Fig. 1. T2DM network. (a) Histogram of the network weights. (b) Disease network for T2DM visualised with Cytoscape [20]. The up-regulated nodes are shown in red colour
and the down-regulated ones in green colour. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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the previous ones, in order to simulate simultaneous actions
of multiple-agents which potentially could act on different tar-
gets. For computational and therapeutic compliance reasons,
the multi-target approach has been restricted to triplets of tar-
gets. The proposed TSDS score is given by:TSDSðA; B;CÞ ¼
Y
t2ðA;B;CÞ
TtoallDPðtÞ ð6Þwhere (A,B,C) is a triplet of targets ST and TtoallDP(t) is obtained
using the Eq. (5). The score is calculated for all the possible combi-
nations of 3 targets in the network.
All the resulting TDSD were normalised using the function:TSDSnormðA;B; CÞ ¼ TSDSðA;B; CÞ minðTSDSÞmaxðTSDSÞ minðTSDSÞ ð7Þ3 This result is also conﬁrmed by deriving a null distribution of the TSDS from 1000
new networks, each resulting from the permutation of the interactions (edges) of the
T2DM network. The number of signiﬁcant triplets identiﬁed with this procedure
increases to 737 and all the 88 triplets already found are present in this new list
Spearman’s rank correlation conﬁrms that the two ranked lists of triplets are closely
related (rho = 0.99).where min(TSDS) and max(TSDS) are the minimum and maximum
values of the previously calculated TSDS, respectively.
2.3. Multi-target candidates identiﬁcation
The ﬁnal goal was the selection of the most signiﬁcant TSDS,
leading to the identiﬁcation of the best target combinations for a
polypharmacological approach. In order to validate the robustness
of our constraints, a null distribution of TSDS values was built by
computing the TSDS for 50,000 combinations of 3 proteins ran-
domly selected from the complete set of nodes.
A measure of the signiﬁcance of the results was assessed by
evaluating the null distribution area to the right of each TSDS ob-
served. The combinations were considered signiﬁcant when they
had a p-value < 0.01.
The resulting targets were further analysed from a pharmaco-
logical and therapeutic point of view, with particular focus on
the biological pathways involved and the modulation (inhibition
or activation) required to restore the equilibrium. Finally, the avail-
ability of standard drugs showing the desired pharmacological pro-
ﬁle was veriﬁed.
3. Results
The network built for the T2DM case, following the method de-
scribed in Section 2, was made of 587 nodes (proteins) and 3683
edges (PPI). The weights distribution of the network’s edges is
shown in Fig. 1(a).
The over- or under- expressed nodes in the network were iden-
tiﬁed from 19 and 6 data sets available in SMD and GEO, respec-tively, so that 87 disease proteins DP were selected (61 down-
expressed and 26 up-expressed). The disease network is shown
in Fig. 1(b). The nodes ST extracted (see Section 2.1.2) were 47 in
total. They were selected out of 14 hub proteins (discarded), 314
druggable nodes (209 of them annotated in STITCH) and 147 bridg-
ing proteins.
The TSDSnorm for each possible combination of 3 ST was calcu-
lated using Eq. (7). The distribution of the resulting TSDSnorm values
is shown in Fig. 2(a). Then, the null distribution (Fig. 2(b)) was car-
ried out to ﬁnd the signiﬁcant TSDS scores. The most signiﬁcant ST
triplets with p-values <0.01 resulted in 88 combinations of 18 dif-
ferent proteins.3
These proteins were further analysed to identify their relation-
ships with the T2DM disease, the biological pathways involved and
the pharmacological modulation needed.
The resulting targets are shown in Table 1. These include pro-
teins with a growth factor function (IGF, TGF, NGF), platelet surface
membrane glycoproteins (GP1BA), which play a crucial role in the
aggregation of platelets, proteins involved in blood coagulation
(FGB, KNG1) and adhesion proteins as the Viniculin (VLC). Also so-
dium channels SCNN1G and SCNN1B as well as amyloid precursor
protein APP (a protein expressed in many tissues and concentrated
in the synapses of neurons) have been identiﬁed among the
targets.
3.1. Robustness evaluation
Since STRING is a repository of known and predicted protein
associations, it may contain false positive associations. Even if we
have considered only the associations deriving from experimental
and database evidences and the interactions with conﬁdence
scores >0.7 (high conﬁdence), we have carried out an analysis to
examine the validity of our observations and the network
robustness.
The presence of false positives has been simulated by randomly
adding a number of proteins corresponding to the 1%, 5% and the
10% of the nodes in the network. The TSDS was computed on the
perturbed networks. In order to evaluate the robustness of the tar-
get triplets identiﬁed so far, we have repeated this procedure for.
Fig. 2. Selection of signﬁcant TSDS.
Table 1
The most frequent targets. The proteins marked with an asterisk need to be activated,
the other ones inhibited.
Protein Name Frequency
IGF1R Insulin-like growth factor1 receptor 74
TGFBR2 Transforming growth factor, beta receptor II 29
VCL* Viniculin 27
APP Amyloid beta (A4) precursor protein 17
IGFBP5 Insulin-like growth factor binding protein 5 17
IGFBP1 Insulin-like growth factor binding protein 1 16
SCNN1G Sodium channel, nonvoltage-gated 1, gamma 14
HCAK1 Immunoglobulin kappa constant 10
NGFR Nerve growth factor receptor 10
FLT4 Fms-related tyrosine kinase 4 9
IGHG1 Immunoglobulin kappa constant 9
IGFBP3 Insulin-like growth factor binding protein 3 7
IGHG1 Immunoglobulin heavy constant gamma 1IDE-
insulin-degrading enzyme
7
FGB Fibrinogen beta chain 6
INSR* Insulin receptor 6
GP1BA Glycoprotein lb 2
KNG1 Kininogen1 2
SCNN1B Sodium channel, nonvoltage-gated 1, beta 2
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were still considered as signiﬁcant. The average results, shown in
Table 2, indicates that our observations are quite robust against
variation of proteins interaction data.4. Discussion
This paper is about a computational platform that integrates
pathways, protein–protein interactions, transcriptional analysis
in order to build in a comprehensive network for multi-target mul-
ti-drug discovery.
Our method is divided into well deﬁned steps in order to be
applicable to other cases, as well as to be easily modiﬁed and
adapted. For instance, we selected the targets that interact with
compounds classiﬁed in ATC (see Section 2.1.2), but this choiceTable 2
Presence of the signiﬁcant (p 0.01) triplets in the perturbed networks.
1% 5% 10%
Mean # of triplets 84.3 (96%) 62.3 (71%) 59.6 (68%)
Std # of triplets 4.19 26.0 19.9can be changed, for example, for drug repurposing, by selecting
only the proteins that have an association with the drug of interest.
The proteins shown in Table 1 represent the most interesting
targets obtained by applying the method developed in the T2DM
case. The most frequent proteins are the binding proteins (IGFBP1,
IGFBP3 and IGFBP5) and the ones that belong to the insulin-like
growth factor family (IGF1R). Experimental data have shown that
IGF1R is a negative regulator of insulin signalling and so, in this
case, an inhibition is the desired action. The deletion of IGF1R also
increases insulin sensitivity [21]. This regulator has also been pro-
posed as a biological ‘‘link’’ between the T2DM and Alzheimer’s
disease (AD). Patients with T2DM have a two- to threefold in-
creased risk for AD. The neuronal resistance for insulin/insulin-like
growth factor-1 might represent a molecular link between T2DM
and AD, characterising AD as ‘‘brain-type diabetes’’ [22]. Currently,
this type of therapeutic approach is not taken into account for
T2DM therapy. However, the inhibition of the IGF/IGF1R system
has been proposed in a phase II clinical trial in prostate cancer,
but without success. Rather interestingly, it has been demon-
strated that a form of nordihydroguaiaretic acid (NDGA or Maso-
procol), an antioxidant extract of Larrea tridentata, decreases both
plasma glucose and triglyceride concentrations in fat-fed/STZ rats
[23]. The nordihydroguaiaretic acid also inhibits the activities of
the IGF1R.
The presence of the amyloid precursor protein APP in the list of
proteins selected as the best targets is very interesting, too. APP is a
diagnostic marker for AD, and a key step in the pathogenesis of AD
is the accumulation of APP in the brain [24]. Recently, it has been
shown that central IGF1R reduces Ab accumulation as well as Ab
toxicity and promotes survival.
The sodium channels SCNN1G and SCNN1B were identiﬁed
among the list of proteins selected as the best targets. These are
nonvoltage-gated and amiloride-sensitive sodium channels that
control the sodium passage and the osmotic diffusion of the water
through the apical membrane of the epithelian cells. SCNN1G and
SCNN1B also control the renal, intestinal and pulmonary reabsorp-
tion of sodium. As shown in Table 1, these proteins have to be
inhibited: in fact, it has been recently demonstrated that the func-
tionality of the pancreatic cells beta insulin-producing can be im-
proved after an amiloride treatment [25]. Moreover amiloride is
able to increase the insulin release and to develop hypoglycemia
[26].
Among the other targets, none with the exception of the insulin
receptor is a known target for T2DM therapy, but each of them has
a strong relation with the T2DM resulting from indirect experi-
mental observations.
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the fact that we built and analysed the network identifying the
genes, and consequently the proteins, whose differential expres-
sion is an effect of the disease. In this way, instead of considering
only the reduced insulin production and supply, which represent
only one of the factors, we took into account the whole disease
context.
5. Conclusions
In this work, we developed a network-based method for a fea-
sible and efﬁcient identiﬁcation of multicomponent synergy that
may be used to treat complex diseases. A disease network has been
built by integrating different sources of data. The targeting of the
network is based on its topological features. In particular, we intro-
duced some constraint on the target proteins in order to better en-
able a polypharmcological approach and to decrease the space of
the potential targets. Finally, we have computed a score (TSDS)
that ranks the combinations of target protein candidates was
deﬁned.
This work has shown the applicability of a network-based ap-
proach to identify potential drug targets by utilising information
extracted from public repositories; in particular, we have studied
the Diabetes type 2 case. The ﬁndings obtained demonstrate that
the method could elucidate interesting interactions and new po-
tential drug targets.
The method developed can be easily modiﬁed, e.g. by perform-
ing combinations of more or less then three targets, by introducing
new target features or relaxing the current constraints.
Our aims were to accelerate and optimise the target and drug
discovery for a polypharmacological-based approach. As future
steps, we will work on reﬁning the protein–protein interaction
analysis, in order to extract the functional relationships between
them. Once the functional interaction will be derived, it will also
be possible to represent the disease network as a directed graph.
Such graph may better describe the interactions as well as how
the information spreads out in the network. The application of
information propagation algorithms may help to better quantify
and verify ‘‘in silico’’ the therapeutic effects on the disease.
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